TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05960682

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
Study: NCT05245812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci SP Surgical System
Description: This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
Study: NCT06567808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: administered as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: administered as outlined
Study: NCT04875637

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WAI-MEMR
Description: Using wideband acoustic reflectance for middle-ear muscle reflex.
Study: NCT04711850

Intervention type: DRUG
Intervention: Imlifidase
Description: Immunoglobulin G degrading enzyme of Streptococcus pyogenes
Study: NCT06420635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children
Description: The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional kangaroo program
Description: The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
Study: NCT05820022

Intervention type: OTHER
Intervention: Research Barriers Scale
Description: This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
Study: NCT05820750

Intervention type: DEVICE
Group type: OTHER
Intervention: photodynamic therapy
Description: root canal treatment of primary molars using photodynamic therapy
Study: NCT06125886

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transvaginal ultrasound and microscale endometrial sampling biopsy
Description: Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
Study: NCT05820750

Intervention type: DEVICE
Group type: OTHER
Intervention: photodynamic therapy
Description: root canal treatment of primary molars using photodynamic therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulpectomy with metapex
Description: root canal treatment using standard technique
Study: NCT05781035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: patients will recieve moderate sedation by dexmedetomidine as study group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia with neuromuscular blockade under controlled ventilation as control group.
Study: NCT05413850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-rhPSMA-10.1 injection
Description: Therapeutic cycles of 177Lu-rhPSMA-10.1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-rhPSMA-10.1 injection
Description: Therapeutic cycles of 177Lu-rhPSMA-10.1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-rhPSMA-10.1 injection
Description: Therapeutic cycles of 177Lu-rhPSMA-10.1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-rhPSMA-10.1 injection
Description: Therapeutic cycles of 177Lu-rhPSMA-10.1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3 injection
Description: 18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3 injection
Description: 18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3 injection
Description: 18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3 injection
Description: 18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
Study: NCT05860049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability
Description: All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization
Description: Each participant in group (B) was seated in a comfortable position. The participant's forehead rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) was applied to the skin around the neck area prior to treatment, and the M2T blade (Figure 4) was cleaned with an alcohol pad. First, the M2T blade was used to find the exact areas of restriction in the RT upper trapezius. Then, the M2T blade was used at an angle of 45°, utilizing treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion for approximately 3 minutes. This procedure was repeated twice a week, for 4 weeks.
Study: NCT04751435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive interview
Description: Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
Study: NCT05864248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supira System
Description: The Supira System is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
Study: NCT05348460

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketone ester drink (DeltaG®, 500 mg/kg body weight)
Description: In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketone ester drink (DeltaG®, 500 mg/kg body weight)
Description: In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Taste-matched, isovolumic placebo drink
Description: In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Taste-matched, isovolumic placebo drink
Description: In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
Study: NCT05060536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of infrapatellar fat pad
Description: There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No removal of infrapatellar fat pad
Description: Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
Study: NCT05244525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Epinephrine
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Study: NCT06164431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 tablet
Description: Participants receive ZSP1273 tablet orally.
Study: NCT05244525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine alone
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Study: NCT06192511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Website and Video
Description: The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
Study: NCT06164431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 tablet
Description: Participants receive ZSP1273 tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zsp1273 granules
Description: Participants receive ZSP1273 granules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zsp1273 granules
Description: Participants receive ZSP1273 granules orally.
Study: NCT06137300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary kallidinogenase for injection
Description: Urinary kallidinogenase 0.15PNA once daily for 7 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Guideline-prescribed medical therapy
Description: Guideline-prescribed medical therapy
Study: NCT06024447

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subgingival Instrumentation
Description: Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
Study: NCT05658081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kono-S group
Description: patients in this arm will receive stapled Kono-S anastomosis after bowel resection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Side-to-side group
Description: patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
Study: NCT06439511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Darwin smartphone app
Description: The participant must look into the smartphone camera with the Darwin app for about 30 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oxymetry
Description: Heart rate will be measured with pulsoe oximetry (gold standard)
Study: NCT06584708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-volume high intensity interval training
Description: Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous exercise
Description: Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes
Study: NCT06314074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oscillometric blood pressure monitoring at 2.5-minute intervals
Description: Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oscillometric blood pressure monitoring at 5-minute intervals
Description: Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
Study: NCT04335292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib First-Line
Description: Osimertinib, 80 mg, oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum + Pemetrexed Chemotherapy Second-Line
Description: Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Third-Line
Description: Rechallenge with osimertinib, 80 mg, oral, daily
Study: NCT05673018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Cancer Early Detection Test (Galleri®)
Description: Blood collection and multi-cancer early detection testing with return of results.
Study: NCT05361798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
Study: NCT06261749

Intervention type: OTHER
Intervention: Voluntary Abdominal Contractions
Description: Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.

Intervention type: OTHER
Intervention: Exercise
Description: Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases.
Study: NCT05361798

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy